US House passage of healthcare reform heralds difficulties ahead
This article was originally published in SRA
Executive Summary
The US House of Representatives has passed a landmark healthcare reform bill that would, among other things, mandate the US government to negotiate Medicare Part D prescription drug prices, introduce a regulatory pathway for biosimilars and prohibit “pay-for-delay” deals between brand name and generic drug companies1.